Sumitomo Mitsui Financial Group’s AbbVie ABBV Stock Holding History

Sumitomo Mitsui Financial Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,000	Closed	-$20K	–	229
2025 Q1	$20K	Buy	+9,000	New	+$1.75M	﹤0.01%	157

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Sumitomo Mitsui Financial Group's ABBV Position: Q2 2025 in Review

Sumitomo Mitsui Financial Group sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 1,230 shares — an estimated $253K sold.

Sumitomo Mitsui Financial Group first reported a position in ABBV in Q1 2018 and held it in 2 quarters. The position peaked at $253K in Q1 2025. 3,781 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

Sumitomo Mitsui Financial Group reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
Sumitomo Mitsui Financial Group sold 1,230 AbbVie shares in Q2 2025, an estimated $253K.
Sumitomo Mitsui Financial Group first reported a position in AbbVie in Q1 2018 and held it in 2 quarters.
Sumitomo Mitsui Financial Group's AbbVie position peaked at $253K in Q1 2025.
3,781 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Sumitomo Mitsui Financial Group's 13F filing for Q2 2025, filed 13 Aug 2025.